Palisade Bio (PALI) Return on Capital Employed (2011 - 2026)
Palisade Bio (PALI) posted quarterly Return on Capital Employed of 20.66% for Q1 2026, up 17904.0% year-over-year from N/an in Q1 2025, and up 24.44% quarter-over-quarter from 27.35% in Q4 2025.
Palisade Bio (PALI) Return on Capital Employed (2011 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Return on Capital Employed for 16 consecutive years, with 20.66% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 17904.0% year-over-year to 20.66%; the TTM figure through Mar 2026 stood at 20.66% (up 17904.0% YoY), while the FY2025 annual figure was 26.56%, up 13442.0% from the prior year.
- Return on Capital Employed improved to 20.66% in Q1 2026 per PALI's latest filing, from 27.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.66% in Q1 2026 and bottomed at 511.14% in Q1 2022.
- Historically, Return on Capital Employed has averaged 182.4% across 5 years, with a median of 149.27% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 33230 bps — and 2023, when it soared 40998 bps.
- Palisade Bio's Return on Capital Employed stood at 120.91% in 2022, then grew by 17 bps to 100.74% in 2023, then slumped by 115 bps to 216.23% in 2024, then soared by 87 bps to 27.35% in 2025, then gained by 24 bps to 20.66% in 2026.
- Business Quant data shows PALI's Return on Capital Employed at 20.66% in Q1 2026, 27.35% in Q4 2025, and 342.82% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | -28.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.26% |
| Mar 31, 2026 | -20.66% |
| Dec 31, 2025 | -27.35% |
| Sep 30, 2025 | -342.82% |
| Jun 30, 2025 | -350.67% |
| Mar 31, 2025 | -199.70% |
| Dec 31, 2024 | -216.23% |
| Sep 30, 2024 | -173.71% |
| Jun 30, 2024 | -149.27% |
| Mar 31, 2024 | -130.58% |
| Dec 31, 2023 | -100.74% |
| Sep 30, 2023 | -91.58% |
| Jun 30, 2023 | -99.71% |
| Mar 31, 2023 | -101.16% |
| Dec 31, 2022 | -120.91% |
| Sep 30, 2022 | -186.55% |
| Jun 30, 2022 | -277.94% |
| Mar 31, 2022 | -511.14% |
| Dec 31, 2021 | -351.81% |
| Sep 30, 2021 | -323.63% |